guidance.fyi
Company, ticker, metric, guidance, or anything said
Q1 FY27
7 Sept 2026
VerifiedNumbers checked and claims independently audited

Transcript ↗

Fischer Medical Ventures LtdPharmaceuticals & HealthcareFISCHER

Q1 FY27 concall · earnings callFischer Medical Ventures Ltd

Fischer Medical Ventures used its September 7, 2026 investor call to present its AI-enabled imaging platform, proprietary technology stack and leadership team, without disclosing quarterly financial results.

Neutral tone2-minute briefPublished 10 days after the call

TL;DR
  • Investor call on September 7, 2026 shared a revised strategic partnership presentation dated June 2026 rather than quarterly results.
  • Presentation described focus on AI-enabled medical imaging, population-scale screening and hospital digitization.
  • Outlined six-pillar proprietary technology stack across magnets, coils, gradients, console, imaging and AI.
  • Listed board of directors and key managerial personnel with backgrounds in healthcare, finance and MRI systems.
Source

Summary written from the transcript filed by Fischer Medical Ventures Ltd for the call held on 7 Sept 2026; published 17 Sept 2026, 17:13 IST.

More Q1 FY27 concalls ·How verification works ·Report an error

Same sector

Others in Pharmaceuticals & Healthcare

All Pharmaceuticals & Healthcare →
  • Symbiotec Pharmalab LimitedQ1 FY27Positive tone

    Q1 FY27 was driven by the established steroid API business while consolidated profit was reduced by operating costs and depreciation from the new biotech CDMO and complex injectables facilities awaiting first revenues in the next 6 to 12 months.

    Consolidated revenue Q1 FY27
    ₹218 Crgrowth of 7% YoY
    API revenue Q1 FY27
    ₹215 Crgrowth of 6% YoY
    SYMBIOTECPharmaceuticals & HealthcareVerified brief6 guidance items
  • Molbio Diagnostics LimitedQ1 FY27Positive tone

    Q1 FY27 was led by the Truenat point-of-care molecular platform with recurring kit sales driving revenue, while management pointed to TB scale-up, HPV rollout, and U.S. and Europe expansion as next growth drivers.

    Revenue from operations (Q1 FY27)
    ₹408 Cr
    EBITDA (Q1 FY27)
    ₹104 Cr
    MOLBIOPharmaceuticals & HealthcareVerified brief3 guidance items
  • Fortis Healthcare LimitedQ1 FY27Positive tone

    Delhi High Court ordered a court-supervised forensic audit into erstwhile promoter share dissipation, IHH's acquisition of control and use of funds for RHT assets, which Fortis and IHH say leaves operations, capex, bed expansion and M&A unrestricted and is expected to have no material adverse outcome.

    FORTISPharmaceuticals & HealthcareVerified brief4 guidance items
  • Orchid Pharma LimitedQ1 FY27Cautious tone

    Quarterly revenue improved 15% year-over-year and EBITDA grew on better gross margins, but the core cephalosporin business continues to face intense industry pricing pressure.

    Revenue from Operations
    ₹304 Crapprox. 15%
    Combined Gross Margin
    33%approx. 3% points
    ORCHPHARMAPharmaceuticals & HealthcareVerified brief6 guidance items
  • Manipal Health Enterprises LimitedQ1 FY27Positive tone

    Manipal Hospitals delivered strong growth in its first quarter as a public company, driven by patient demand, high-acuity specialty care, and the integration of Sahyadri Hospitals.

    Revenue from Operations
    ₹3,091 Cr38.1%
    EBITDA
    ₹749 Cr26.4%
    MANIPALHOSPharmaceuticals & HealthcareVerified brief3 guidance items